Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To evaluate quetiapine XR in patients with anxious depression, as defined by HAM-A total and HAM-D anxiety/somatisation factor scores. METHODS: Post hoc analyses of pooled data from two 6-week, double-blind, randomised, placebo-controlled studies of adjunctive quetiapine XR (150 or 300 mg/day) in patients with MDD and inadequate response to antidepressants. Patients were stratified in a primary analysis using HAM-A (HAM-A total score at baseline ≥ 20 ["high"] or < 20 ["low"]) and a secondary analysis using HAM-D (anxious depression defined as HAM-D anxiety/somatisation factor score ≥ 7). Outcomes included change in MADRS total score. RESULTS: In patients with high anxiety levels (HAM-A total score ≥ 20), reductions in MADRS total score were -15.20 (P = 0.122) and -15.92 (P < 0.05) for quetiapine XR 150 and 300 mg/day, respectively, vs. placebo (-13.49). In patients with low levels of anxiety (HAM-A total score < 20), both quetiapine XR doses (P < 0.001) improved MADRS total scores vs. placebo. In the secondary analysis, quetiapine XR 150 (P < 0.01) and 300 mg/day (P < 0.001) improved MADRS total score vs. placebo in patients with HAM-D anxiety/somatisation factor score ≥ 7. CONCLUSIONS: Adjunct quetiapine XR demonstrates efficacy in patients with anxious and non-anxious depression, assessed using HAM-A total score, and anxious depression assessed using HAM-D anxiety/somatisation factor score.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DSM-III-R Generalized Anxiety Disorder in the National Comorbidity Survey
Wittchen, H.-U. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950050015002 · Cited by 967 · cited 1×
“Symptoms of anxiety are present in most patients with MDD (Kessler et al. 1996; Bandelow 2003) and patients with GAD often experience symptoms of depression (Wittchen et al. 1994; Murphy et al. 2004).”
BackgroundFava, M., Rush, A. J., Alpert, J. E., Balasubramani, G. K., Wisniewski, S. R., Carmin, C. N., Biggs, M. M., Zisook, S., Leuchter, A., Howland, R., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111868 · Cited by 927
Roy-Byrne, P. P., Stang, P., Wittchen, H.-U., Ustun, B., Walters, E. E., & Kessler, R. C. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.3.229 · Cited by 446 · cited 1×
“…and poorer outcomes and these patients may have higher levels of social distress, suicide rates, incidence of alcohol and drug abuse, and use of healthcare services than patients without comorbid conditions (Brown et al. 1996; Kessler et al. 1996; Roy-Byrne et al. 2000; Belzer and Schneier 2004).”
BackgroundTreatment outcomes for primary care patients with major depression and lifetime anxiety disorders.
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.10.1293 · Cited by 312 · cited 1×
“…and poorer outcomes and these patients may have higher levels of social distress, suicide rates, incidence of alcohol and drug abuse, and use of healthcare services than patients without comorbid conditions (Brown et al. 1996; Kessler et al. 1996; Roy-Byrne et al. 2000; Belzer and Schneier 2004).”
BackgroundRemission and relapse in major depression: a two-year prospective follow-up study
Ramana, R., Paykel, E. S., Cooper, Z., Hayhurst, H., Saxty, M., & Surtees, P. G. (1995) · Psychological Medicine · doi:10.1017/s0033291700033134 · Cited by 236 · cited 1×
“In addition, residual anxiety symptoms can reduce the likelihood of remission (McIntyre et al. 2007; Kurian et al. 2009) and, following initial therapy, can increase rates of recurrence (Ramana et al. 1995; Flint and Rifat 1997; Dombrovski et al. 2007).”
BackgroundBELZER, K., & SCHNEIER, F. R. (2004) · Journal of Psychiatric Practice · doi:10.1097/00131746-200409000-00003 · Cited by 235 · cited 1×
“…and poorer outcomes and these patients may have higher levels of social distress, suicide rates, incidence of alcohol and drug abuse, and use of healthcare services than patients without comorbid conditions (Brown et al. 1996; Kessler et al. 1996; Roy-Byrne et al. 2000; Belzer and Schneier 2004).”
BackgroundImpact of Comorbid Anxiety Disorders on Outcome in a Cohort of Patients With Bipolar Disorder
Boylan, K. R., Bieling, P. J., Marriott, M., Begin, H., Young, L. T., & MacQueen, G. M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0813 · Cited by 215
Bauer, M., Pretorius, H. W., Constant, E. L., Earley, W. R., Szamosi, J., & Brecher, M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04629 · Cited by 210
Self-citationBandelow, B., Chouinard, G., Bobes, J., Ahokas, A., Eggens, I., Liu, S., & Eriksson, H. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990423 · Cited by 142
Self-citationHirschfeld, R. M. A., Weisler, R. H., Raines, S. R., Macfadden, W., & BOLDER Study Group (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0304 · Cited by 116 · cited 1×
“Quetiapine immediate release (300 and 600 mg) once daily monotherapy has demonstrated signifi cant effi cacy in the treatment of anxiety in patients with bipolar depression, as assessed using the HAM-A (Week 8 change, 9.9 and 10.8 vs. 6.7 for placebo, respectively; P 0.001) (Hirschfeld et al. 2006).”
MethodInfluential
Cited by
Gaspersz, R., Nawijn, L., Lamers, F., & Penninx, B. W. J. H. (2018) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000376 · Cited by 139
McIntyre, R. S., Weiller, E., Zhang, P., & Weiss, C. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.05.013 · Cited by 36
McIntyre, R. S., Rodrigues, N. B., Lipsitz, O., Nasri, F., Gill, H., Lui, L. M., Subramaniapillai, M., Kratiuk, K., Teopiz, K., Ho, R., et al. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120954048 · Cited by 20
Ziprasidone augmentation for anxious depression
Ionescu, D. F., Shelton, R. C., Baer, L., Meade, K. H., Swee, M. B., Fava, M., & Papakostas, G. I. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000133 · Cited by 10
“…efficacy for quetiapine versus placebo in patients with anxious depression (with a mean difference in reduction in Montgomery–Asberg Depression Rating Scale scores in patients treated with 150 or 300 mg of adjunctive quetiapine versus placebo of 2.6 and 3.3, respectively) (Bandelow et al., 2014).”
BackgroundInfluentialHeo, J.-Y., Jeon, H. J., Fava, M., Mischoulon, D., Baer, L., Clain, A., Doorley, J., Pisoni, A., & Papakostas, G. I. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.01.007 · Cited by 6
Metadata
- Authors
- Bandelow, B., Bauer, M., Vieta, E., El-Khalili, N., Gustafsson, U., Earley, W. R., & Eriksson, H.
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2014-02
- Volume
- 15
- Issue
- 2
- Pages
- 155-166
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W2110323314
- Cited by
- 18
- References
- 13
- FWCI
- 2.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline. https://app.cochat.ai/papers/10.3109/15622975.2013.842654
- The paper
- Bandelow, B., Bauer, M., Vieta, E., El-Khalili, N., Gustafsson, U., Earley, W. R., & Eriksson, H. (2014). Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline. The World Journal of Biological Psychiatry. https://doi.org/10.3109/15622975.2013.842654
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.